Is Globeimmune Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Globeimmune Inc (GBIM) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Globeimmune Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Globeimmune Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Globeimmune Inc?

Muslim investors may consider investing in Globeimmune Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Globeimmune Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Globeimmune Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Globeimmune Inc updated?

The Shariah compliance status of Globeimmune Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Globeimmune Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Globeimmune Inc?

You can check the latest Shariah compliance status of Globeimmune Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Globeimmune Inc. Stock Analysis GBIM

United States Health Care Nano Cap

GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. The company has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The firm's oncology product candidates include GI-6301, GI-6207 and GI-4000. The firm's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.

Key Statistics of Globeimmune Inc (GBIM)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.00$0.00

Today's Open

$0.00

Volume

25.91K

P/E Ratio (TTM)

52 Week Range

$0.00$0.00

Market Cap

575.20

Avg. Volume

10.99K

Dividend Yield

Financial Metrics & Statements of Globeimmune Inc (GBIM)

FAQ's for Globeimmune Inc (GBIM)

According to Musaffa’s Shariah screening methodology, Globeimmune Inc (GBIM) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.